Ventyx Biosciences Inc (VTYX) concluded trading on Thursday at a closing price of $1.82, with 7.98 million shares of worth about $14.52 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.82% during that period and on May 22, 2025 the price saw a gain of about 18.95%. Currently the company’s common shares owned by public are about 71.16M shares, out of which, 63.06M shares are available for trading.
Stock saw a price change of 50.41% in past 5 days and over the past one month there was a price change of 56.90%. Year-to-date (YTD), VTYX shares are showing a performance of -16.89% which decreased to -62.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.78 but also hit the highest price of $5.66 during that period. The average intraday trading volume for Ventyx Biosciences Inc shares is 1.04 million. The stock is currently trading 36.43% above its 20-day simple moving average (SMA20), while that difference is up 47.97% for SMA50 and it goes to -3.41% lower than SMA200.
Ventyx Biosciences Inc (NASDAQ: VTYX) currently have 71.16M outstanding shares and institutions hold larger chunk of about 63.00% of that.
The stock has a current market capitalization of $129.52M and its 3Y-monthly beta is at 0.77. It has posted earnings per share of -$1.75 in the same period. It has Quick Ratio of 19.57 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VTYX, volatility over the week remained 8.97% while standing at 6.94% over the month.
Stock’s fiscal year EPS is expected to rise by 4.21% while it is estimated to decrease by -0.09% in next year. EPS is likely to grow at an annualized rate of 1.46% for next 5-years, compared to annual growth of -87.13% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on March 12, 2024 offering an Overweight rating for the stock and assigned a target price range of between $7 and $16 to it. Coverage by Oppenheimer stated Ventyx Biosciences Inc (VTYX) stock as an Outperform in their note to investors on March 12, 2024, suggesting a price target of $12 for the stock. On November 07, 2023, Wells Fargo Downgrade their recommendations, while on November 07, 2023, Stifel Downgrade their ratings for the stock with a price target of $6. Stock get a Perform rating from Oppenheimer on November 07, 2023.
